Letrozole: An updated review of its use in postmenopausal women with advanced breast cancer

American Journal of Cancer

Volumn 1, Issue 5, 2002, Pages 351-371

  Keating, Gillian M ^a   Jarvis, Blair ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; CORTICOSTEROID; ESTRADIOL; ESTROGEN; ESTRONE; ESTRONE SULFATE; EXEMESTANE; FADROZOLE; FORMESTANE; LETROZOLE; MEGESTROL; TAMOXIFEN;

ANTINEOPLASTIC ACTIVITY; APPETITE DISORDER; AROMATIZATION; BONE METABOLISM; BREAST CANCER; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; ENZYME INHIBITION; FATIGUE; FEMALE; HAIR DISEASE; HOT FLUSH; HUMAN; IN VITRO STUDY; NAUSEA; NONHUMAN; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TREATMENT OUTCOME; UTERUS WEIGHT; VAGINA BLEEDING; WEIGHT GAIN;

EID: 0042378908     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200201050-00007     Document Type: Review

References (85)

1. Njar VCO, Brodie AMH. Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. Drugs 1999; 58: 233-55
2. Clemons M, Goss P. Estrogens and the risk of breast cancer, N Engl J Med 2001 Jan 25; 344 (4): 276-85
3. Higa GM. New generation aromatase inhibitors in breast cancer. Pharmacoeconomics 2000 Feb; 17 (2): 121-32
4. Buzdar AU. Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol 2001 Jun; 28 (3): 291-304
5. Lamb HM, Adkins JC. Letrozole: a review of its use in postmenopausal women with advanced breast cancer, Drugs 1998; 56: 1125-40
6. Cohen MH, Johnson JR, Li N, et al. Approval summary: letrozole in the treatment of posrmenopausal women with advanced breast cancer. Clin Cancer Res 2002 Mar; 8 (3): 665-9
7. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001 Nov; 12 (11): 1527-32
8. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001 Sep; 19 (18): 3808-16
9. Dixon JM, Love CDB, Bellamy COC, et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 2001 Apr; 66: 191-9
10. Shaw HS, Ellis MJ. Letrozole in the treatment of breast cancer. Expert Opin Pharmacother 2002 May; 3 (5): 607-17
11. Michaud LB, Buzdar AU. Risks and benefits of aromatase inhibitors in postmenopausal breast cancer. Drug Saf 1999; 21: 297-309
12. Miller WR. Biology of aromatase inhibitors: pharmacology/endocrinology within the breast. Endocr. Relat. Cancer. 1999; 6: 187-95
13. Miller WR, Dixon JM. Local endocrine effects of aromatase inhibitors within the breast. J Steroid Biochem Mol Biol 2001 Dec; 79 (1-5): 93-102
14. Bhatnagar AS, Batzl C, Häusler A, et al. Pharmacology of nonsteroidal aromatase inhibitors. In: Pasqualini JR, Katzenellenbogen BS. editors. Hormone-dependent cancer. New York: Marcel Dekker. Inc., 1996: 155-68
15. Kao Y-C, Cam LL, Laughton CA, et al. Binding characteristics of seven inhibitors of human aromatase: a site-directed mutagenesis study. Cancer Res 1996; 56: 3451-60
16. Kudoh M, Susaki Y, Ideyama Y, et al. The potent and selective inhibition of estrogen production by non-steroidal aromatase inhibitor, YM511. J Steroid Biochem Mol Biol 1995; 54: 265-71
17. Dowsett M, Jones A, Johnston SRD, et al. In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995; 1: 1511-5
18. Lønning PE. Pharmacology of new aromatase inhibitors. Breast 1996; 5 (3): 202-8
19. Geisler J, Haynes B, Anker G, et al. Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002 Feb 1; 20 (3): 751-7
20. Iveson TJ, Smith IE, Ahern J, et al. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in healthy postmenopausal women. J Clin Endocrinol Metab 1993; 77: 324-31
21. Iveson TJ, Smith IE, Ahern J, et al. Phase I study of the oral nonsteroidal aromatase inhibitor CGS 20267 in postmenopausal patients with advanced breast cancer. Cancer Res 1993; 53: 266-70
22. Lipton A, Demers LM, Harvey HA, et al. Letrozole (CGS 20267): a phase I study of a new potent oral aromatase inhibitor of breast cancer. Cancer 1995; 75: 2132-8
23. Demers LM. Effects of fadrozole (CGS 16949A) and letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients. Breast Cancer Res Treat 1994; 30 (1): 95-102
24. Klein KO, Demers LM, Santner SJ, et al. Use of ultrasensitive recombinant cell bioassay to measure estrogen levels in women with breast cancer receiving the aromatase inhibitor, letrozole. J Clin Endocrinol Metab 1995; 80: 2658-60
25. Lu Q, Liu Y, Long BJ, et al. The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer. Breast Cancer Res Treat 1999; 57: 183-92
26. Brodie A, Lu Q, Yue W, et al. Intratumoral aromatase model: the effects of letrozole (CGS 20267). Breast Cancer Res Treat 1998; 49 (Suppl.): S23-6
27. Yue W, Wang J, Savinov A, et al. Effect of aromatase inhibitors on growth of mammary tumors in a nude mouse model. Cancer Res 1995; 55: 3073-7
28. Lu Q, Yue W, Wang J, et al. The effects of aromatase inhibitors and antiestrogens in the nude mouse model. Breast Cancer Res Treat 1998; 50: 63-71
29. Long BJ, Jelovac D, Thiantanawat A, et al. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clin Cancer Res 2002 Jul; 8 (7): 2378-88
30. Long BJ, Jelovac D, Thiantanawat A, et al. The effect of alternating letrozole and tamoxifen in comparison to sequential treatment with each drug alone or in combination [abstract no. 444 and poster]. Breast Cancer Res Treat 2001 Oct; 69 (3): 287
31. Schieweck K, Bhatnagar AS, Batzl C, et al. Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mamniary tomors. J Steroid Biochem Mol Biol 1993; 44: 633-6
32. Bajetta E, Zilembo N, Dowsett M, et al. Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients. Eur J Cancer 1999; 35: 208-13
33. Heshmati HM, Khosla S, Robins SP, et al. Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. J Bone Miner Res 2002 Jan; 17 (1): 172-8
34. Harper-Wynne C, Ross G, Sacks N, et al. Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 2002 Jul; 11 (7): 614-21
35. Elisal MS, Bairaktari ET, Nicolaides C, et al. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001; 37: 1510-3
36. Brodie A, Lu Q, Long B, Aromatase and its inhibitors. J Steroid Biochem Mol Biol 1999; 69: 205-10
37. Pfister CU, Martoni A, Zamagni C, et al. Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. Biopharm Drug Dispos 2001 Jul; 22 (5): 191-7
38. Sioufi A, Gauducheau N, Pineau V, et al. Absolute bioavailability of letrozole in healthy postmenopausal women, Biopharm Drug Dispos 1997; 18: 779-89
39. Colussi DM, Parisot CY, Lefevre GY. Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor. J Clin Pharmacol 1998; 38: 727-35
40. Sioufi A, Sandrenan N, Godbillon J, et al. Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2. 5 mg single oral administration. Biopharm Drug Dispos 1997; 18: 489-97
41. Novartis. Femara® (letrozole tablets) prescribing information [online]. Available from URL: http://www.femara.com [Accessed 2001 Jul 18]
42. Wirz B, Valles B, Parkinson A, et al. CYP3A4 and CYP2A6 are involved in the biotransformation of letrozole (®Femara) [abstract]. 7th North American Meeting of the International Society for the Study of Xenobiotics; 1996 Oct 20-24; San Diego (CA), 40
43. Pfister CU, Horak J, Horejsova M, et al. Pharmacokinetics of Femara® in subjects with severe liver impairment [abstract no. 2926]. Proceedings of the American Association for Cancer Research 2001 Mar; 42: 544
44. Dowsett M, Pfister C, Johnston SR, et al. Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res 1999; 5: 2338-43
45. Ingle JN, Suman VJ, Johnson PA, et al. Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer. Clin Cancer Res 1999; 5: 1642-9
46. Morgan JM, Palmisano M, Spencer S, et al. Pharmacokinetic effect of cimetidine on a single 2.5 mg dose of letrozole in healthy subjects [abstract no. 26]. J Clin Pharmacol 1996; 36: 852
47. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-606
48. Mouridsen H, Sun Y, Gershanovich M, et al. First-line therapy with letrozole (Femara®) for advanced breast cancer prolongs time to worsening of Karnofsky Performance Status (KPS) compared with tamoxifen [abstract no. 458 and poster]. Breast Cancer Res Treat 2001 Oct; 69 (3): 291
49. Dranitsaris G, Verma S, Trudeau M. Cost utility of first line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to tamoxifen [poster]. 24th Annual San Antonio Breast Cancer Symposium; 2001 Dec 10-13; San Antonio (TX)
50. Karnon JD, Jones TED. A stochastic economic evaluation of letrozole versus tamoxifen as a first-line therapy for postmenopausal women with advanced breast cancer [abstract no. 853]. Eur J Cancer 2001 Oct; 37 (Suppl. 6): S232
51. Gersharovich M, Chaudri HA, Campos D, et al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer, Ann Oncol 1998; (9): 639-45
52. Dombernowsky P, Smith I, Falkson G, et al. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453-61
53. Buzdar A, Douma J, Davidson N, et al. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001 Jul 15; 19 (14): 3357-66
54. Rose C, Vtoraya O, Pluzanska A, et al. Letrozole (Femara) vs. anastrozole (Arimidex): second-line treatment in postmenopausal women with advanced breast cancer [abstract no. 131]. Proceedings of the American Society of Clinical Oncology 2002; 21 (Pt 1): 34a
55. Tominaga T, Morimoto T, Ohashi J, et al. A pivotal double-blind trial in Japan of an aromatase inhibitor letrozole (third generation) vs. its predecessor fadrozole hydrochloride (second generation): Japan Letrozole Study Group [abstract no. 100]. Ann Oncol 2000; 11 (Suppl. 4): 25
56. Ingle JN, Johnson PA, Suman VJ, et al. A randomized phase II trial of two dosage levels of letrozole as third-line hormonal therapy for women with metastatic breast carcinoma. Cancer 1997; 80: 218-24
57. Tominaga T, Ohashi Y, Abe R, et al. Phase II trial of letrozole (a novel oral nonsteroidal aromatase inhibitor) in postmenopausal patients with advanced or recurrent breast cancer [abstract no. 490]. Eur J Cancer 1998; (31A): S81
58. Chaudri HA, Trunet PF. Letrozole: updated duration of response [letter]. J Clin Oncol 1999; 17: 3856-60
59. Gershanovich M, Chaudri HA, Hornberger U, et al. Comparison of letrozole 2.5 mg (Femara®) with megestrol acetate (MA) and with aminoglutethimide (AG) in patients with visceral disease [abstract no. 212]. Breast Cancer Res Treat 1998; 46: 53
60. Gardin G, Fornasiero A, Romieu G, et al. Long duration of response with letrozole 2.5 mg (Femara®) in two trials in postmenopausal women with advanced breast cancer after anti-estrogen therapy [abstract no. 461. Eur J Cancer 1998 Sep; 34 (Suppl. 5): S13-4
61. Possinger K, Schmid P, Wischnewsky MB. Letrozole is highly effective in patients with soft tissue metastases [abstract no. 171]. Breast Cancer Res Treat 2000; 64: 53
62. Wischnewsky MB, Schmid P, Boehm R, et al. Letrozole and megestrol acetate in patients with advanced breast cancer resistant to tamoxifen [abstract no. 174]. Breast Cancer Res Treat 2000; 64: 54
63. Thomas R, Makris A, Bloomfield D, et al. Empowering patients to make informed treatment decisions based on tolerability, quality of life patient preference: a comparison of letrozole and anastrozole in a multicentre, randomised, single-blind cross over study [abstract no. 171 and poster]. Eur J Cancer 2002 Mar; 38 (Suppl. 3): S83
64. Nuijten M, Meester L, Waibel F, et al. Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK. Pharmacoeconomics 1999; 16 (4): 379-91
65. Nuijten M, McCormick J, Waibel F, et al. Economic evaluation of letrozole in the treatment of advanced breast cancer in postmenopausal women in Canada. Value Health 2000; 3 (1): 31-9
66. Dranitsaris G, Leung P, Mather J, et al. Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. Anticancer Drugs 2000; 11: 591-601
67. European Agency for the Evaluation of Medicinal Products. European summary of product characteristics for letrozole [online]. Available from URL: http://www.emea.eu.int [Accessed 2002 Sep 12]
68. Lønning PE. Is there a growing role for endocrine therapy in the treatment of breast cancer? Drugs 2000; 60: 11-21
69. National Comprehensive Cancer Network. NCCN Practice Guidelines for Breast Cancer. Oncology 2000 Nov; 14 (11 A): 33-49
70. National Comprehensive Cancer Network. NCCN Practice Guidelines for Breast Cancer [online]. Available from URL: http://www.nccn.org [Accessed 2002 Sep 11]
71. Bonneterre J, Thürlimann B, Robertson JFR, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000 Nov 15; 18: 3748-57
72. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol 2000 Nov 15; 18: 3758-67
73. Buzdar A, Nabholtz JM, Robertson JF, et al. Anastrozole (Arimidex) versus tamoxifen as first-line therapy for advanced breast cancer (Abc) in postmenopausal (Pro) women - combined analysis from two identically designed multicenter trials [abstract no. 609D]. Proceedings of the American Society of Clinical Oncology 2000; 19: 154
74. Thürlimann B, Beretta K, Bacchi M, et al. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer: prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol 1996; 7: 471-9
75. Falkson CI, Falkson HC. A ramdomised study of CGS-16949A (fadrozole) versus tamoxifen in previously untreated postmenopausal patients with metastatic breast cancer, Ann Oncol 1996; 7: 465-9
76. Paridaens R, Dirix LY, Beex L, et al. Exemestane (Aromasin) is active and well tolerated as first-line hormonal therapy (HT) of metastatic breast cancer (MBC) patients (Pts): results of a randomized phase II trial [abstract no. 316], Proceedings of the American Society of Clinical Oncology 2000; 19: 83
77. Jonat W, Howell A, Blomqvist C, et al. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 1996; 32A: 404-12
78. Buzdar AU, Jones SE, Vogel CL, et al. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer 1997 Feb 15; 79: 730-9
79. Buzdar AU, Jonat W, Howell A, et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer 1998 Sep 15; 83: 1142-52
80. Buzdar AU, Smith R, Vogel C, et al. Fadrozole HC1 (CGS-16949A) versus megestrol acetate treatment of postmenopausal patients with metastatic breast carcinoma: results of two randomized double-blind controlled multiinstitutional trials. Cancer 1996 Jun 15; 77: 2503-13
81. Kvinnsland S, Anker G, Dirix L-Y, et al. High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment. Eur J Cancer 2000; 36: 976-82
82. Kaufmann M, Bajetta E, Dirix LY, et al. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol 2000 Apr; 18: 1399-411
83. Thürlimann B, Castiglione M, Hsu-Schmitz SF, et al. Formestane versus megestrol acetate in postmenopausal breast cancer patients after failure of tamoxifen: a phase III prospective randomised cross over trial of second-line hormonal treatment (SAKK 20/90). Eur J Cancer 1997; 33: 1017-24
84. Lipton A, Ali SM, Leitzel K, et al. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol 2002 Mar 15; 20 (6): 1467-72
85. Goss PE, Strasser K. Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001 Feb 1; 19 (3): 881-94